Llwwhh personal page - To The Moon

Llwwhh

Llwwhh

No personal profile

8Follow

0Followers

0Topic

0Badge

2021-06-28

Nio

Ford Or NIO? The Final Verdict

2021-06-28

Wow

5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021

2021-06-27

Too the moon

2021-06-26

Stuck with this

2021-06-21

Bullish

2021-06-18

Bear or bull now

2021-06-18

$ARK Innovation ETF(ARKK)$Pls soar

2021-05-27

$Bionano Genomics(BNGO)$Play long game

2021-05-25

Future tesla?

2021-05-23

Lookin good

2021-05-16

Now ? Or never

2021-05-10

Like and comment

5 Unbeatable Stocks to Buy for a Biden Bull Market

2021-05-10

It was good now trash?

Bearish Bets: 2 Tech Stocks You Should Consider Shorting This Week

2021-05-09

Software is the best

2021-05-09

Coins

2021-05-07

Red is my new colour

2021-05-04

Hello

2021-05-03

Buy the dips on blockvhain stocks

2021-05-01

GEVO looks goood

2021-04-17

Solid

Bionano Genomics fell about 10% in Friday morning trading

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3566354699453607","uuid":"3566354699453607","gmtCreate":1603268588866,"gmtModify":1615773698711,"name":"Llwwhh","pinyin":"llwwhh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":53,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.55%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":127480579,"gmtCreate":1624863196092,"gmtModify":1703846475867,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Nio","listText":"Nio","text":"Nio","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127480579","repostId":"1137119316","repostType":4,"repost":{"id":"1137119316","kind":"news","pubTimestamp":1624754401,"share":"https://ttm.financial/m/news/1137119316?lang=&edition=fundamental","pubTime":"2021-06-27 08:40","market":"us","language":"en","title":"Ford Or NIO? The Final Verdict","url":"https://stock-news.laohu8.com/highlight/detail?id=1137119316","media":"seekingalpha","summary":"I am comparing Ford against NIO in different categories.The comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.NIO is growing a lot faster than Ford and the high valuation may be justified.With Ford  launching a major offensive in the market for electric vehicles, Chinese EV maker NIO  will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based ","content":"<p><b>Summary</b></p>\n<ul>\n <li>I am comparing Ford against NIO in different categories.</li>\n <li>The comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.</li>\n <li>NIO is growing a lot faster than Ford and the high valuation may be justified.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5033fa117d7852799244b8275bc1000f\" tg-width=\"1536\" tg-height=\"886\"><span>peterschreiber.media/iStock via Getty Images</span></p>\n<p>With Ford (F) launching a major offensive in the market for electric vehicles, Chinese EV maker NIO (NIO) will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based on market opportunity, scale, revenue model, growth prospects and valuation? I will compare Ford against NIO in each category and issue a final verdict at the end.</p>\n<p><b>Ford vs. NIO: The battle for the global electric vehicle market is heating up</b></p>\n<p>Although there is a world of difference between Ford and NIO, both companies are set to go toe-to-toe in the rapidly growing global electric vehicle market. Ford’s fleet is not yet EV-focused but this is going to change: Feeling that the EV race is heating up, Ford said it is accelerating its electrification plan by investing&nbsp;$30B into its EV manufacturing capabilities until 2025. Ford’s previous capital plan called for a $22B investment in zero-emission vehicles. Ford also set an ambitious sales goal: 40% of its global sales will be electric within the next decade and 33% of pickup truck sales. Electric vehicle sales account for just 1% of Ford's sales today. As Ford is phasing out combustion engines, it is set to evolve into an all-electric vehicle maker by 2040.</p>\n<p><b>Market opportunity</b></p>\n<p>In 2020, 3.2m electric vehicles were sold in the world which represented a small market share of just 4.2%. China, however, was responsible for buying 41% of all electric vehicles in the world in 2020. Chinese buyers purchased 1.3m electric vehicles last year and sales are set to grow fast as Beijing seeks to boost EV adoption. The second largest market for electric vehicles was Europe which accounted for 42% of global EV sales. The US is only the third-largest market for plug-in electric vehicles in the world.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b48c23b32134542f51227d9b1b612887\" tg-width=\"1083\" tg-height=\"863\"><span>(Source: Wikipedia)</span></p>\n<p>China, by far, is the fastest growing EV market in the world, although Europe is catching up fast, in part due to a legislative efforts to increase adoption of zero-emission passenger vehicles and because of massive investments in a Europe-wide charging station network. NIO is&nbsp;on the cusp of entering the European market&nbsp;in a bid to grow market share in the world’s second-largest EV market before the competition is ready.</p>\n<p>Beijing is a driver behind the electrification of the Chinese auto industry: The government wants to see a&nbsp;twenty percent share&nbsp;of electric vehicles for new car sales by 2025 which will drive EV penetration in NIO’s home market.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9871e44eaf69adb27151425887870ace\" tg-width=\"739\" tg-height=\"454\"><span>(Source:Schroders)</span></p>\n<p>Turning to growth projections.</p>\n<p>With more favorable government policies for EV makers in places like China and Europe, these markets are poised to see the fastest sales growth and the highest EV adoption rates in the world. China is not only the largest market due to population size but is also expected to outperform all other markets in the world in EV sales until 2030.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/61d19dff2f34e2d8828aca854e85d84a\" tg-width=\"825\" tg-height=\"565\"><span>(Source:McKinsey)</span></p>\n<p>Since China has a larger total market size, a higher EV adoption rate, stronger expected sales growth and a more favorable regulatory framework, the winner here would be: NIO.</p>\n<p><b>Scale and manufacturing competence</b></p>\n<p>Ford has a century’s worth of manufacturing experience. But Ford, so far, has only one all-electric vehicle in its product line-up that compares to NIO: The Mustang Mach-E SUV. In 2022, Ford will begin to sell the all-electric F-150 Lightening which builds on the success of Ford’s best-selling pick-up truck. NIO already has a stronger product catalog including the 5-seater ES6 SUV, the 5-seater coupe SUV EC6 and the ES8, a 6-seater and 7-seater full-sized SUV.</p>\n<p>Since NIO is solely focused on producing EVs and occupies a very small and defined niche, the Chinese firm has an advantage as far as EV-manufacturing expertise goes. The question is how long this advantage can last. Ford has extensive experience in building cars and can leverage a global manufacturing base to ramp up EV production faster than any niche EV maker could ever hope to achieve. This makes Ford a very serious rival not only to Tesla (TSLA) in the US, but also to NIO abroad. Ford is accelerating its electrification plans and it has the resources and the ambition to become a leader in EVs within the next decade. Ford’s proposed $30B spending on the electrification of its fleet will accelerate its transformation and turn Ford into a long term threat to other EV makers.</p>\n<p>Winner here: Ford.</p>\n<p><b>Differentiation and BaaS revenue model</b></p>\n<p>Both Ford and NIO know about the importance of differentiation in a market that will only get more competitive over time, which is why both companies are investing heavily in a related field that can break or solidify dominance in the EV market: Battery technology.</p>\n<p>Ford is&nbsp;forming a joint venture&nbsp;with South Korean battery technology company SK Innovation to secure supply of traction battery cells and array modules. The joint venture is meant to accelerate battery deliveries and will produce approximately 60 GWh annually, enough to cover 25% of Ford’s estimated annual energy demand by 2030. NIO is also investing in battery technology and has&nbsp;formed its own joint venture&nbsp;to secure battery supply.</p>\n<p>The difference to Ford is that NIO’s battery investment strategy revolves around a battery subscription model, also called “battery-as-a-service”, which creates a strong, long term revenue opportunity for the Chinese vehicle maker. Under this “BaaS” model, users who buy a NIO electric vehicle get a 70,000 RMB initial discount, equivalent to $10,800, and can sign up for a monthly subscription to rent a rechargeable 70 kWh battery. Batteries can then be exchanged at one of NIO’s battery-swapping stations which can be found in most big Chinese cities. A battery subscription costs 980 RMB monthly which is the equivalent of $150.</p>\n<p>The BaaS model has a couple of benefits for both the vehicle maker and the user: Purchasing an electric vehicle from NIO gets a lot more affordable due to the up-front discount and the subscription model ensures that users benefit from advancement in battery technology and better performance over time. Decoupling battery costs from vehicle prices creates an entirely new revenue stream on a subscription basis for NIO. Revenues from “BaaS” subscriptions could be used to increase the density of NIO’s network of charging/replacement stations. The battery subscription model also binds customers to NIO, potentially increasing customer lifetime value.</p>\n<p>Ford and NIO are primed to benefit from falling battery costs for electric vehicles as they ramp up capital allocations. As more investments flow into developing more efficient batteries, performance will go up and costs will go down which should drive EV adoption and benefit all EV makers. This is because lower battery prices make EVs more competitive to passenger vehicles with combustion engines. But since NIO is structuring a part of its business model explicitly around battery subscriptions, NIO could benefit more than Ford.</p>\n<p>Battery costs for EVs have decreased 70% since 2014, based on information provided by investment firm Schroders, and are set to decrease more this decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c42acb75905affe7570a2f399ea3192f\" tg-width=\"758\" tg-height=\"449\"><span>(Source: Schroders)</span></p>\n<p>The “BaaS” model is genius and could develop into a $500M a year revenue opportunity for NIO long term. Although Ford is ramping up its investments in battery technology, the winner in this category is: NIO.</p>\n<p><b>Sales growth and valuation</b></p>\n<p>Ford’s sales in May grew 4.1% Y/Y but electrified vehicle sales (including hybrids) surged 184% Y/Y as Ford sold a record 10,364 EVs/hybrids in May. Escape electrified sales and Explorer Hybrid grew sales at 125% and 132% Y/Y showing strong customer uptake. NIO delivered 6,711 vehicles last month including 3,017 ES6s, 1,412 ES8s and 2,282 EC6s. Total Y/Y delivery growth for May was 95.3%.</p>\n<p>Ford's sales are fifty-four times larger than NIO's which creates more sales growth and revaluation potential for NIO.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df5a0a393e44ed74241c5effcdd92350\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p>\n<p>The difference in valuation between Ford and NIO is like the difference between night and day. This is because Ford is still seen as a mature vehicle maker with expected enterprise sales growth in the low-to-mid digits, despite explosive growth in the EV category. Ford is expected to grow revenues by 33% until FY 2025 (base year: FY 2020) and NIO by 808%!</p>\n<p>Due to these differences in sales growth, NIO is the complete opposite of Ford, at least as far as valuation goes. The Chinese EV-maker is expected to see sales and delivery growth close to 100% this year and since NIO is only dealing in EVs, NIO gets a much higher market-cap-to-sales ratio than Ford.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/817605c6b1e82c03d0473ea570d32b8f\" tg-width=\"506\" tg-height=\"406\"><span>(Source: Author)</span></p>\n<p><b>NIO has larger risks...</b></p>\n<p>NIO is the more risky venture, but also the one that offers the most promise. Government policy favors EV-makers like NIO. The potential for total global sales growth is larger for NIO as it operates from a smaller revenue base compared to Ford. But there are also a few things that work against NIO. For example, recalls due to production defects would be a much bigger challenge for NIO to overcome than for Ford which can rely on a global service and distribution network. NIO’s valuation is also not without risk as an unexpected slowing of sales growth due to production setbacks would leave a much larger dent in the financials.</p>\n<p><b>Final verdict</b></p>\n<p>NIO is definitely the more “sexy” vehicle maker. Strong adoption and sales growth in China and Europe support NIO. Its super smart BaaS model which decouples vehicle purchase prices from battery costs is genius. You pay a high price for this growth but the market opportunity for NIO is immense.</p>\n<p>Ford’s EV sales are booming and the percentage of EV sales will increase as the vehicle maker electrifies its fleet. Ford has a lot of potential in the EV market but since EV sales are still a relatively low percentage of total sales, it will take a long time for Ford to complete its transformation.</p>\n<p>If you believe in the potential of the global EV market, buy NIO. If you believe in the potential of the global EV market and don’t like much risk, buy Ford.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford Or NIO? The Final Verdict</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord Or NIO? The Final Verdict\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nI am comparing Ford against NIO in different categories.\nThe comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137119316","content_text":"Summary\n\nI am comparing Ford against NIO in different categories.\nThe comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.\nNIO is growing a lot faster than Ford and the high valuation may be justified.\n\npeterschreiber.media/iStock via Getty Images\nWith Ford (F) launching a major offensive in the market for electric vehicles, Chinese EV maker NIO (NIO) will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based on market opportunity, scale, revenue model, growth prospects and valuation? I will compare Ford against NIO in each category and issue a final verdict at the end.\nFord vs. NIO: The battle for the global electric vehicle market is heating up\nAlthough there is a world of difference between Ford and NIO, both companies are set to go toe-to-toe in the rapidly growing global electric vehicle market. Ford’s fleet is not yet EV-focused but this is going to change: Feeling that the EV race is heating up, Ford said it is accelerating its electrification plan by investing $30B into its EV manufacturing capabilities until 2025. Ford’s previous capital plan called for a $22B investment in zero-emission vehicles. Ford also set an ambitious sales goal: 40% of its global sales will be electric within the next decade and 33% of pickup truck sales. Electric vehicle sales account for just 1% of Ford's sales today. As Ford is phasing out combustion engines, it is set to evolve into an all-electric vehicle maker by 2040.\nMarket opportunity\nIn 2020, 3.2m electric vehicles were sold in the world which represented a small market share of just 4.2%. China, however, was responsible for buying 41% of all electric vehicles in the world in 2020. Chinese buyers purchased 1.3m electric vehicles last year and sales are set to grow fast as Beijing seeks to boost EV adoption. The second largest market for electric vehicles was Europe which accounted for 42% of global EV sales. The US is only the third-largest market for plug-in electric vehicles in the world.\n(Source: Wikipedia)\nChina, by far, is the fastest growing EV market in the world, although Europe is catching up fast, in part due to a legislative efforts to increase adoption of zero-emission passenger vehicles and because of massive investments in a Europe-wide charging station network. NIO is on the cusp of entering the European market in a bid to grow market share in the world’s second-largest EV market before the competition is ready.\nBeijing is a driver behind the electrification of the Chinese auto industry: The government wants to see a twenty percent share of electric vehicles for new car sales by 2025 which will drive EV penetration in NIO’s home market.\n(Source:Schroders)\nTurning to growth projections.\nWith more favorable government policies for EV makers in places like China and Europe, these markets are poised to see the fastest sales growth and the highest EV adoption rates in the world. China is not only the largest market due to population size but is also expected to outperform all other markets in the world in EV sales until 2030.\n(Source:McKinsey)\nSince China has a larger total market size, a higher EV adoption rate, stronger expected sales growth and a more favorable regulatory framework, the winner here would be: NIO.\nScale and manufacturing competence\nFord has a century’s worth of manufacturing experience. But Ford, so far, has only one all-electric vehicle in its product line-up that compares to NIO: The Mustang Mach-E SUV. In 2022, Ford will begin to sell the all-electric F-150 Lightening which builds on the success of Ford’s best-selling pick-up truck. NIO already has a stronger product catalog including the 5-seater ES6 SUV, the 5-seater coupe SUV EC6 and the ES8, a 6-seater and 7-seater full-sized SUV.\nSince NIO is solely focused on producing EVs and occupies a very small and defined niche, the Chinese firm has an advantage as far as EV-manufacturing expertise goes. The question is how long this advantage can last. Ford has extensive experience in building cars and can leverage a global manufacturing base to ramp up EV production faster than any niche EV maker could ever hope to achieve. This makes Ford a very serious rival not only to Tesla (TSLA) in the US, but also to NIO abroad. Ford is accelerating its electrification plans and it has the resources and the ambition to become a leader in EVs within the next decade. Ford’s proposed $30B spending on the electrification of its fleet will accelerate its transformation and turn Ford into a long term threat to other EV makers.\nWinner here: Ford.\nDifferentiation and BaaS revenue model\nBoth Ford and NIO know about the importance of differentiation in a market that will only get more competitive over time, which is why both companies are investing heavily in a related field that can break or solidify dominance in the EV market: Battery technology.\nFord is forming a joint venture with South Korean battery technology company SK Innovation to secure supply of traction battery cells and array modules. The joint venture is meant to accelerate battery deliveries and will produce approximately 60 GWh annually, enough to cover 25% of Ford’s estimated annual energy demand by 2030. NIO is also investing in battery technology and has formed its own joint venture to secure battery supply.\nThe difference to Ford is that NIO’s battery investment strategy revolves around a battery subscription model, also called “battery-as-a-service”, which creates a strong, long term revenue opportunity for the Chinese vehicle maker. Under this “BaaS” model, users who buy a NIO electric vehicle get a 70,000 RMB initial discount, equivalent to $10,800, and can sign up for a monthly subscription to rent a rechargeable 70 kWh battery. Batteries can then be exchanged at one of NIO’s battery-swapping stations which can be found in most big Chinese cities. A battery subscription costs 980 RMB monthly which is the equivalent of $150.\nThe BaaS model has a couple of benefits for both the vehicle maker and the user: Purchasing an electric vehicle from NIO gets a lot more affordable due to the up-front discount and the subscription model ensures that users benefit from advancement in battery technology and better performance over time. Decoupling battery costs from vehicle prices creates an entirely new revenue stream on a subscription basis for NIO. Revenues from “BaaS” subscriptions could be used to increase the density of NIO’s network of charging/replacement stations. The battery subscription model also binds customers to NIO, potentially increasing customer lifetime value.\nFord and NIO are primed to benefit from falling battery costs for electric vehicles as they ramp up capital allocations. As more investments flow into developing more efficient batteries, performance will go up and costs will go down which should drive EV adoption and benefit all EV makers. This is because lower battery prices make EVs more competitive to passenger vehicles with combustion engines. But since NIO is structuring a part of its business model explicitly around battery subscriptions, NIO could benefit more than Ford.\nBattery costs for EVs have decreased 70% since 2014, based on information provided by investment firm Schroders, and are set to decrease more this decade.\n(Source: Schroders)\nThe “BaaS” model is genius and could develop into a $500M a year revenue opportunity for NIO long term. Although Ford is ramping up its investments in battery technology, the winner in this category is: NIO.\nSales growth and valuation\nFord’s sales in May grew 4.1% Y/Y but electrified vehicle sales (including hybrids) surged 184% Y/Y as Ford sold a record 10,364 EVs/hybrids in May. Escape electrified sales and Explorer Hybrid grew sales at 125% and 132% Y/Y showing strong customer uptake. NIO delivered 6,711 vehicles last month including 3,017 ES6s, 1,412 ES8s and 2,282 EC6s. Total Y/Y delivery growth for May was 95.3%.\nFord's sales are fifty-four times larger than NIO's which creates more sales growth and revaluation potential for NIO.\nData by YCharts\nThe difference in valuation between Ford and NIO is like the difference between night and day. This is because Ford is still seen as a mature vehicle maker with expected enterprise sales growth in the low-to-mid digits, despite explosive growth in the EV category. Ford is expected to grow revenues by 33% until FY 2025 (base year: FY 2020) and NIO by 808%!\nDue to these differences in sales growth, NIO is the complete opposite of Ford, at least as far as valuation goes. The Chinese EV-maker is expected to see sales and delivery growth close to 100% this year and since NIO is only dealing in EVs, NIO gets a much higher market-cap-to-sales ratio than Ford.\n(Source: Author)\nNIO has larger risks...\nNIO is the more risky venture, but also the one that offers the most promise. Government policy favors EV-makers like NIO. The potential for total global sales growth is larger for NIO as it operates from a smaller revenue base compared to Ford. But there are also a few things that work against NIO. For example, recalls due to production defects would be a much bigger challenge for NIO to overcome than for Ford which can rely on a global service and distribution network. NIO’s valuation is also not without risk as an unexpected slowing of sales growth due to production setbacks would leave a much larger dent in the financials.\nFinal verdict\nNIO is definitely the more “sexy” vehicle maker. Strong adoption and sales growth in China and Europe support NIO. Its super smart BaaS model which decouples vehicle purchase prices from battery costs is genius. You pay a high price for this growth but the market opportunity for NIO is immense.\nFord’s EV sales are booming and the percentage of EV sales will increase as the vehicle maker electrifies its fleet. Ford has a lot of potential in the EV market but since EV sales are still a relatively low percentage of total sales, it will take a long time for Ford to complete its transformation.\nIf you believe in the potential of the global EV market, buy NIO. If you believe in the potential of the global EV market and don’t like much risk, buy Ford.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127480112,"gmtCreate":1624863148736,"gmtModify":1703846476029,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127480112","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=fundamental","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","AMZN":"亚马逊","BRK.B":"伯克希尔B","MA":"万事达","BMY":"施贵宝","BAC":"美国银行","TEVA":"梯瓦制药"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124347280,"gmtCreate":1624749864240,"gmtModify":1703844287882,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Too the moon","listText":"Too the moon","text":"Too the moon","images":[{"img":"https://static.tigerbbs.com/ad88954b860291e3c4cbf03d2de7d640","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124347280","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125343381,"gmtCreate":1624660673543,"gmtModify":1703842859213,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Stuck with this&nbsp;","listText":"Stuck with this&nbsp;","text":"Stuck with this","images":[{"img":"https://static.tigerbbs.com/33329919565e24cea00d1925d984567f","width":"1125","height":"2875"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/125343381","isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167557395,"gmtCreate":1624279256617,"gmtModify":1703832246818,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Bullish","listText":"Bullish","text":"Bullish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167557395","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168843439,"gmtCreate":1623972504221,"gmtModify":1703824889566,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Bear or bull now&nbsp;","listText":"Bear or bull now&nbsp;","text":"Bear or bull now","images":[{"img":"https://static.tigerbbs.com/7105443940aa52cf5330961d9f3fa436","width":"1125","height":"2785"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168843439","isVote":1,"tweetType":1,"viewCount":495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":168840066,"gmtCreate":1623972418355,"gmtModify":1703824884602,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ARKK\">$ARK Innovation ETF(ARKK)$</a>Pls soar","listText":"<a href=\"https://laohu8.com/S/ARKK\">$ARK Innovation ETF(ARKK)$</a>Pls soar","text":"$ARK Innovation ETF(ARKK)$Pls soar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168840066","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132201636,"gmtCreate":1622088996725,"gmtModify":1704179253736,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Play long game&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Play long game&nbsp;","text":"$Bionano Genomics(BNGO)$Play long game","images":[{"img":"https://static.tigerbbs.com/52e4bff3412353809e657f68daf0df30","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132201636","isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":138678529,"gmtCreate":1621938638361,"gmtModify":1704364769020,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Future tesla?","listText":"Future tesla?","text":"Future tesla?","images":[{"img":"https://static.tigerbbs.com/ce009d2c2c0da98e301bd22d49c7d1b8","width":"1125","height":"2695"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138678529","isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":133114590,"gmtCreate":1621727317410,"gmtModify":1704361704816,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Lookin good","listText":"Lookin good","text":"Lookin good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/133114590","isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192159557,"gmtCreate":1621166750779,"gmtModify":1704353546540,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Now ? Or never&nbsp;","listText":"Now ? Or never&nbsp;","text":"Now ? Or never","images":[{"img":"https://static.tigerbbs.com/9941b78171b3d7d24573e71d6ad68ff3","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192159557","isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190479716,"gmtCreate":1620648844335,"gmtModify":1704346073201,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190479716","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://ttm.financial/m/news/1171756066?lang=&edition=fundamental","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion","AZN":"阿斯利康","MA":"万事达","NLY":"Annaly Capital Management","GOOGL":"谷歌A"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190447923,"gmtCreate":1620648534462,"gmtModify":1704346068438,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"It was good now trash?","listText":"It was good now trash?","text":"It was good now trash?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190447923","repostId":"1106333988","repostType":2,"repost":{"id":"1106333988","kind":"news","pubTimestamp":1620617869,"share":"https://ttm.financial/m/news/1106333988?lang=&edition=fundamental","pubTime":"2021-05-10 11:37","market":"us","language":"en","title":"Bearish Bets: 2 Tech Stocks You Should Consider Shorting This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1106333988","media":"realmoney","summary":"Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opp","content":"<p>Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.</p>\n<p>Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet'sQuant Ratings, we zero in on five names.</p>\n<p>While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.</p>\n<p><b>Alteryx</b></p>\n<p>Alteryx Inc. (AYX) &nbsp;recently was downgraded to<b>Sell</b>with a D+ rating by TheStreet's<b>Quant Ratings.</b></p>\n<p><img src=\"https://static.tigerbbs.com/7afc1fc2f19b5149d4cb10eea02cc5d7\" tg-width=\"986\" tg-height=\"889\" referrerpolicy=\"no-referrer\"></p>\n<p>This provider of analytics platforms has fallen hard since peaking in early February. Rough earnings stoked the selling and it has been straight down ever since. The channel is not symmetrical, but we can see a series of lower highs and lower lows.</p>\n<p>Money flow is poor and the Relative Strength Index (RSI) cannot seem to get going. This tells us Alteryx is relatively poor versus the rest of the market. Moving average convergence divergence (MACD) is on a sell signal and the cloud is deep red.</p>\n<p>If short, target a move to $65 or so but put in a stop at $83.</p>\n<p><b>Pinterest</b></p>\n<p>Pinterest Inc.&nbsp; (PINS) &nbsp;recently was downgraded to<b>Sell</b>with a D+ rating by TheStreet's<b>Quant Ratings.</b></p>\n<p><img src=\"https://static.tigerbbs.com/6b1e181ed1151d1395ae59a7035382df\" tg-width=\"999\" tg-height=\"891\" referrerpolicy=\"no-referrer\"></p>\n<p>The company behind the popular app of the same name has been beaten like a piñata lately, with a gap lower on earnings and not much energy from the dip buyers. The stock continues to be distributed with high volume and a MACD sell signal.</p>\n<p>The cloud just turned red and the 200-day moving average is not far below here. A gap is still open in the $40s and that could be the place to target if short.</p>\n<p>Put in a stop at $75 just in case.</p>","source":"lsy1619508253632","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bearish Bets: 2 Tech Stocks You Should Consider Shorting This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBearish Bets: 2 Tech Stocks You Should Consider Shorting This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 11:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580><strong>realmoney</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.\nUsing technical analysis of the charts of those stocks, and, when ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AYX":"Alteryx Inc.","PINS":"Pinterest, Inc."},"source_url":"https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106333988","content_text":"Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.\nUsing technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet'sQuant Ratings, we zero in on five names.\nWhile we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.\nAlteryx\nAlteryx Inc. (AYX)  recently was downgraded toSellwith a D+ rating by TheStreet'sQuant Ratings.\n\nThis provider of analytics platforms has fallen hard since peaking in early February. Rough earnings stoked the selling and it has been straight down ever since. The channel is not symmetrical, but we can see a series of lower highs and lower lows.\nMoney flow is poor and the Relative Strength Index (RSI) cannot seem to get going. This tells us Alteryx is relatively poor versus the rest of the market. Moving average convergence divergence (MACD) is on a sell signal and the cloud is deep red.\nIf short, target a move to $65 or so but put in a stop at $83.\nPinterest\nPinterest Inc.  (PINS)  recently was downgraded toSellwith a D+ rating by TheStreet'sQuant Ratings.\n\nThe company behind the popular app of the same name has been beaten like a piñata lately, with a gap lower on earnings and not much energy from the dip buyers. The stock continues to be distributed with high volume and a MACD sell signal.\nThe cloud just turned red and the 200-day moving average is not far below here. A gap is still open in the $40s and that could be the place to target if short.\nPut in a stop at $75 just in case.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190088806,"gmtCreate":1620553191105,"gmtModify":1704344920087,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Software is the best&nbsp;","listText":"Software is the best&nbsp;","text":"Software is the best","images":[{"img":"https://static.tigerbbs.com/46b8fd859467b6a79bbce92a9ddd3531","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190088806","isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190088921,"gmtCreate":1620553139063,"gmtModify":1704344919764,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Coins","listText":"Coins","text":"Coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190088921","isVote":1,"tweetType":1,"viewCount":470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":104536972,"gmtCreate":1620397157696,"gmtModify":1704343137097,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Red is my new colour","listText":"Red is my new colour","text":"Red is my new colour","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/104536972","isVote":1,"tweetType":1,"viewCount":478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106504651,"gmtCreate":1620130771273,"gmtModify":1704339041893,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Hello&nbsp;","listText":"Hello&nbsp;","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106504651","isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108246630,"gmtCreate":1620034507220,"gmtModify":1704337654971,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Buy the dips on blockvhain stocks","listText":"Buy the dips on blockvhain stocks","text":"Buy the dips on blockvhain stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108246630","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101038488,"gmtCreate":1619829632244,"gmtModify":1704335407492,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"GEVO looks goood","listText":"GEVO looks goood","text":"GEVO looks goood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/101038488","isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370555499,"gmtCreate":1618614990811,"gmtModify":1704713354391,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Solid&nbsp;","listText":"Solid&nbsp;","text":"Solid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/370555499","repostId":"1151923129","repostType":4,"repost":{"id":"1151923129","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618581789,"share":"https://ttm.financial/m/news/1151923129?lang=&edition=fundamental","pubTime":"2021-04-16 22:03","market":"us","language":"en","title":"Bionano Genomics fell about 10% in Friday morning  trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151923129","media":"Tiger Newspress","summary":"(April 16) Bionano Genomics fell about 10% in Friday morning trading.\nThere's a genomics revolution ","content":"<p>(April 16)&nbsp;Bionano Genomics&nbsp;fell&nbsp;about&nbsp;10%&nbsp;in Friday morning trading.</p>\n<p>There's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b>(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p>\n<p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p>\n<p>Many investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p>\n<p><img src=\"https://static.tigerbbs.com/4d6d3a8298b2b720b7b4ddcf26507750\" tg-width=\"708\" tg-height=\"500\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics fell about 10% in Friday morning  trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics fell about 10% in Friday morning  trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-16 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 16)&nbsp;Bionano Genomics&nbsp;fell&nbsp;about&nbsp;10%&nbsp;in Friday morning trading.</p>\n<p>There's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b>(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p>\n<p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p>\n<p>Many investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p>\n<p><img src=\"https://static.tigerbbs.com/4d6d3a8298b2b720b7b4ddcf26507750\" tg-width=\"708\" tg-height=\"500\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151923129","content_text":"(April 16) Bionano Genomics fell about 10% in Friday morning trading.\nThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.\nBionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.\nMany investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":101038488,"gmtCreate":1619829632244,"gmtModify":1704335407492,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"GEVO looks goood","listText":"GEVO looks goood","text":"GEVO looks goood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/101038488","isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127480112,"gmtCreate":1624863148736,"gmtModify":1703846476029,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127480112","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=fundamental","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","AMZN":"亚马逊","BRK.B":"伯克希尔B","MA":"万事达","BMY":"施贵宝","BAC":"美国银行","TEVA":"梯瓦制药"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125343381,"gmtCreate":1624660673543,"gmtModify":1703842859213,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Stuck with this&nbsp;","listText":"Stuck with this&nbsp;","text":"Stuck with this","images":[{"img":"https://static.tigerbbs.com/33329919565e24cea00d1925d984567f","width":"1125","height":"2875"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/125343381","isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":132201636,"gmtCreate":1622088996725,"gmtModify":1704179253736,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Play long game&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Play long game&nbsp;","text":"$Bionano Genomics(BNGO)$Play long game","images":[{"img":"https://static.tigerbbs.com/52e4bff3412353809e657f68daf0df30","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132201636","isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190479716,"gmtCreate":1620648844335,"gmtModify":1704346073201,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190479716","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://ttm.financial/m/news/1171756066?lang=&edition=fundamental","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRUP":"Trupanion","AZN":"阿斯利康","MA":"万事达","NLY":"Annaly Capital Management","GOOGL":"谷歌A"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340679302,"gmtCreate":1617412092906,"gmtModify":1704699467596,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Coins pls","listText":"Coins pls","text":"Coins pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340679302","repostId":"1112964874","repostType":4,"repost":{"id":"1112964874","kind":"news","pubTimestamp":1617358490,"share":"https://ttm.financial/m/news/1112964874?lang=&edition=fundamental","pubTime":"2021-04-02 18:14","market":"us","language":"en","title":"Value Stocks Have Roared Back. Here Are 6 Funds for the Rally’s Next Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1112964874","media":"Barron's","summary":"Value managers are in the midst of what finally looks like a comeback. The questions for investors n","content":"<p>Value managers are in the midst of what finally looks like a comeback. The questions for investors now are just how long this value recovery can last, and how best to ride it.</p><p>The recovery comes as investors peel themselves away from pricey growth stocks to add some of the cheaper companies that are well positioned for a global economic rebound as the world emerges from the pandemic. And it follows a decade of underperformance that has been hard on the most battle-hardy contrarians. Storied value fund firms—including GMO, Royce Investment Partners, and Third Avenue Management—have suffered sharp outflows over the past decade, according toMorningstar.International Value Advisers, better known as IVA, announced in March that it would liquidate its two funds and shut down. Other value funds have shuttered or gravitated toward growthier fare in order to survive.</p><p>Yet things seem different now. Over the past couple of months, the Russell 1000 Value has outperformed the Russell 1000 Growth by the biggest margin in about two decades. That has offered some redemption for veteran value managers, such as the $28 billionOakmark International(ticker: OAKIX) manager David Herro, who recalls the pushback last spring when he gave clients his rationale for buyingDaimler(DAI.Germany) as its price cratered.</p><p>“Clients were saying, ‘Don’t you know we are going into a recession?’ You have to have the courage of conviction,” says Herro, who cited the company’s strong balance sheet and management. “If you didn’t stay true to your ditty, you don’t get the recovery we experienced in the second and fourth quarters.”</p><p>And what a recovery it has been. Funds like Herro’s saw returns of 50% or greater in the past year, repairing long-term performance records that had been tarnished by the past decade’s rough patch. Value, of course, comes in different flavors, and the recovery so far has been kindest to value managers who loaded up on deeply unloved materials, energy, and financial companies.</p><p>Rising interest rates have been a major catalyst for the shift toward value. But valuations, a recovery in profits, and portfolios that are underweight value stocks could keep the momentum going. However, the type of value stock that does better could shift as the year goes on, from lower-quality to higher-quality stocks that boast stronger returns on assets, equity, and capital, according to a recent client note from Bank of America strategist Savita Subramanian.</p><p>Investors looking to benefit from a value comeback might want a mix of funds positioned from the different stages of the recovery, in the U.S. and abroad. Here are six funds run by veteran managers with strong track records that have also done well in the past year’s rebound.</p><p>The $4.3 billionNeuberger Berman Large Cap Valuefund (NPNAX) bet big last year on some of the market’s most unloved sectors and reaped the rewards, returning 84% in the past year and beating 96% of its Morningstar peers.</p><p>Manager Eli Salzmann focused on sectors like materials, especially copper and gold, that have been starved for capital in recent years as money flocked to technology and consumer-discretionary companies. That “capacity deprivation” sets the stage for sharp margin growth as demand recovers for companies like Freeport-McMoRan (FCX). Not only does the copper miner benefit from a global economic recovery, but it’s also a backdoor into the shift to electric vehicles and clean energy—transitions that will require more copper and could extend the traditional recovery cycle, says Salzmann.</p><p>A similar trend is at play in energy, a sector that Salzmann says is learning from its mistakes, as companies allocate 60% to 80% of cash flows, rather than all of it, to capital spending.Exxon Mobil(XOM) has been a “dog of the dogs,” pursuing an aggressive growth strategy when investors wanted discipline and a focus on free cash flow, Salzmann says. But now, the company, a top holding, is focusing on its core business and has the right asset mix.</p><p>When the market fretted over the risks on banks’ loan portfolios last spring, Salzmann went on a shopping spree, adding to financials, including global giants likeBank of America(BAC) andJPMorgan Chase(JPM), as well as regional banks likeTruist Financial(TFC),Comerica(CMA), andRegions Financial(RF) that should get a bigger boost from loan growth and rising interest rates. Salzmann sees a more protracted, broader value recovery as the market enters a higher interest-rate environment amid the unprecedented amounts of fiscal and monetary policy around the world, as well as a period of deglobalization and increased protectionism that will raise prices.</p><p>Like Salzmann, Herro has been hunting in deeply unloved parts of the market—but abroad. That has taken him to continental Europe and the United Kingdom, which investors have neglected for roughly a decade amid concerns about defaults in countries like Greece, political volatility, and, more recently, Brexit. “It’s almost like the perfect storm after 10 years of a drought. Brexit is behind us, and a lot of what ailed European and international value is now in the rearview,” Herro says.</p><p>As the U.K. recovers from the pandemic and settles into life outside the European Union, Herro says strong and “severely overcapitalized” banks likeLloyds Banking Group(LYG) andNatWest Group(NWG) will benefit from pent-up demand for investing and borrowing that had been put off amid Brexit uncertainty.</p><p>Herro has also waded into Chinese internet companies during the sector’s rout in the past year.Alibaba GroupHolding (BABA) andTencent Holdings(700.Hong Kong), which Herro owns through South African internet groupNaspers(NPN.South Africa), have been hit hard in the past year amid regulatory concerns at home and geopolitical tensions with the U.S., creating value in companies with strong business models, he says.</p><p>Sarah Ketterer, co-manager of the $5.8 billionCauseway International Value(CIVVX), isn’t shopping much in the most battered sectors and isn’t sold on a meaningful rise in interest rates. Ketterer also thinks that the party in cyclicals may be winding down, especially after the 80% gains globally in these economically sensitive stocks since the first Covid-19 vaccine won approval late last year—another reason that traditional value sectors like financials and energy don’t interest her much. These sectors also face constraints to their growth, with energy, for example, facing an expensive long-term transition away from fossil fuels.</p><p>Instead, Ketterer sees more value these days in European drugmakers likeSanofi(SAN.France),Novartis(NOVN.Switzerland), andRoche Holding(ROG.Switzerland), which have suffered amid postponed elective surgeries and doctors’ visits. The companies are positioned for a recovery but also for a world where vaccines become more important, and ample free cash flow gives these companies the wherewithal to buy machine learning and other tools to speed up drug discovery and cut costs, says Ketterer.</p><p>Technology companies likeSAP(SAP) are also on her radar. “It’s a legacy software vendor—about as negative as it gets—but 70% of revenues are sticky,” Ketterer says. Plus, Ketterer says the company is led by a young, dynamic CEO, Christian Klein, who is in the early stages of a cloud transition and also taking subsidiaries public, creating what she describes as “one of those rare opportunities.”</p><p>Unlike Ketterer,Dodge &amp; Cox International Stock(DODFX) co-manager Diana Strandberg still sees upside in some of the cyclical sectors that have led the recovery—like financials, which account for 30% of the fund, including holdings such asBNP Paribas(BNP.France) andUBS Group(UBSG.Switzerland), and emerging market banks like India’sICICI Bank(IBN).</p><p>Many European and emerging market banks have spent the past decade rebuilding their capital and balance sheets, increasing their returns on assets and earnings power—and doing it in Europe against a negative interest-rate backdrop. Yet Strandberg says investors haven’t noticed that these banks aren’t what they were during the financial crisis. Earnings revisions are rising, yet many still trade at eight to 10 times earnings. Plus, since banks had to hold off on dividends and buybacks during the pandemic, Strandberg sees the possibility of these companies becoming big income stocks as capital distributions are resumed.</p><p>However, Strandberg cautions against a dogmatic approach and focusing on labels like deep value or relative value—or even classifying certain sectors or companies as value. The $42 billion value fund, which has about a fifth of assets in emerging markets, returned 4.6% on average over the past 15 years, beating 93% of its peers. “Labels are dangerous when you are investing,” Strandberg says. “The starting point matters, and that’s why we are always measuring valuations and fundamentals, but we keep an open mind and not just think we are a value manager so we buy ‘value’ stocks—not only is that changing, but also sometimes stocks are cheap because they should be.”</p><p>More recently, Strandberg and team have favored pharmaceuticals over consumer staples. While their valuations are similar, Strandberg sees greater upside from drugmakers’ research and development. She has favored companies that are in the midst of a restructuring or ones that are focused on areas like vaccines, immunology, and rare diseases that are more protected from regulatory concerns.</p><p>Restructuring opportunities are also attractive to T. Rowe Price Value (TRVLX) fund manager Mark Finn. He has been focusing lately on companies in the middle of the value spectrum—those not facing long-term problems—that are misunderstood or addressing self-inflicted problems, likeGeneral Electric(GE), which had made some ill-timed acquisitions and saddled its balance sheet with leverage. Now, though, Finn says that CEO Larry Culp is fixing many of the issues, and the company includes strong businesses like aircraft engines, power, and healthcare.</p><p>Finn, whose fund returned an average annual 12.1% over the past decade to beat 92% of peers, scooped up banks, discount retailers, and industrials likeDeere(DE) andCaterpillar(CAT) last spring, but is now looking elsewhere. “The cyclicals don’t scream real cheap right now. There’s a lot of optimism built into those.”</p><p>Instead, Finn sees more value in companies likeProcter &amp; Gamble(PG). The company is cheap, at 20 times cash flow, compared with its historical valuation and is in the midst of a turnaround. It has taken share in its major markets and has an underleveraged balance sheet, Finn says.</p><p>He also likes utilities such asDominion Energy(D) andXcel Energy(XEL) that have been hit as investors pursue higher-yielding options amid rising interest rates. Also attractive:Sherwin-Williams(SHW), which he says is cheap compared with historical valuations and tethered to the home-building and remodeling boom.</p><p>While not traditional value fare, technology companies, includingFacebook(FB) andSalesforce.com(CRM), have drawn Finn’s attention. He says Salesforce has a great business model that is well positioned for the recovery, but the stock is in investor no-man’s land, ignored by growth investors and not on value managers’ radar, even though it is in the Russell 1000 Value index.</p><p>Technology is also a heavy weighting at the $4 billionParnassus Endeavorfund (PARWX), which has beaten 98% of its peers over the past year without owning any energy or materials stocks. Since taking the sole reins after sustainable-investing pioneer Jerome Dodson’s retirement, fund manager Billy Hwan has increased risk management, reducing the heavy concentration in chip companies. Hwan has reallocated some of that money to higher-quality software and service companies likePaychex(PAYX), which he says is well positioned to help companies navigate remote work, flexible hours, and contractor relationships. While chip companies face a risk from continuing U.S.-China tensions, since they get more than half of sales from China, efforts to bolster U.S. chip production could help holdings likeMicron Technology(MU) andIntel(INTC).</p><p>The fund, which integrates environmental, social, and governance factors into its analysis, steers clear of deep value and areas in secular decline, instead focusing on higher-quality stocks that are misunderstood, likeHanesbrands(HBI). The company had struggled with acquisitions and competition in its underwear business, but new management is reducing the amount of products it sells and focusing on its fast-growing Champion brand, while also trying to cater to a younger demographics, Hwan says.</p><p>Stimulus has helped cushion household savings and given consumers a bit more to spend as they emerge from the pandemic. Hwan sees 2021 as the year of the consumer, a reason that 10% of the fund is in consumer credit companies likeMastercard(MA),American Express(AXP), andCapital One Financial(COF).</p><p>For investors looking for comparisons with other value rallies, Hwan sees more similarities between the current comeback and the one in 2000 after the dot-com bubble burst, than the recovery after the global financial crisis that tripped up value managers. “There’s nothing structurally wrong with the economy in terms of credit” as there was after the financial crisis, he says, “so I think the value rotation could last several years.”</p><p>Only time will tell whether he’s correct in his assessment, but investors may want to take a more holistic view of value as they try to ride the recovery in the near term.</p><p><b>Searching for Value</b></p><p>As the value rally runs on, investors should start gearing up for a shift in the nature of stocks that perform best. Here are six value-focused funds positioned to capitalize on different stages of the recovery.</p><p><img src=\"https://static.tigerbbs.com/777263e6adccebc217617670fa958673\" tg-width=\"638\" tg-height=\"698\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/b6835876c5ae79da6f50d326590d76e1\" tg-width=\"636\" tg-height=\"362\" referrerpolicy=\"no-referrer\"></p><p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Value Stocks Have Roared Back. Here Are 6 Funds for the Rally’s Next Stage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValue Stocks Have Roared Back. Here Are 6 Funds for the Rally’s Next Stage\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-02 18:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/value-stocks-have-roared-back-here-are-6-funds-for-the-rallys-next-stage-51617289914?mod=hp_columnists><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Value managers are in the midst of what finally looks like a comeback. The questions for investors now are just how long this value recovery can last, and how best to ride it.The recovery comes as ...</p>\n\n<a href=\"https://www.barrons.com/articles/value-stocks-have-roared-back-here-are-6-funds-for-the-rallys-next-stage-51617289914?mod=hp_columnists\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/value-stocks-have-roared-back-here-are-6-funds-for-the-rallys-next-stage-51617289914?mod=hp_columnists","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112964874","content_text":"Value managers are in the midst of what finally looks like a comeback. The questions for investors now are just how long this value recovery can last, and how best to ride it.The recovery comes as investors peel themselves away from pricey growth stocks to add some of the cheaper companies that are well positioned for a global economic rebound as the world emerges from the pandemic. And it follows a decade of underperformance that has been hard on the most battle-hardy contrarians. Storied value fund firms—including GMO, Royce Investment Partners, and Third Avenue Management—have suffered sharp outflows over the past decade, according toMorningstar.International Value Advisers, better known as IVA, announced in March that it would liquidate its two funds and shut down. Other value funds have shuttered or gravitated toward growthier fare in order to survive.Yet things seem different now. Over the past couple of months, the Russell 1000 Value has outperformed the Russell 1000 Growth by the biggest margin in about two decades. That has offered some redemption for veteran value managers, such as the $28 billionOakmark International(ticker: OAKIX) manager David Herro, who recalls the pushback last spring when he gave clients his rationale for buyingDaimler(DAI.Germany) as its price cratered.“Clients were saying, ‘Don’t you know we are going into a recession?’ You have to have the courage of conviction,” says Herro, who cited the company’s strong balance sheet and management. “If you didn’t stay true to your ditty, you don’t get the recovery we experienced in the second and fourth quarters.”And what a recovery it has been. Funds like Herro’s saw returns of 50% or greater in the past year, repairing long-term performance records that had been tarnished by the past decade’s rough patch. Value, of course, comes in different flavors, and the recovery so far has been kindest to value managers who loaded up on deeply unloved materials, energy, and financial companies.Rising interest rates have been a major catalyst for the shift toward value. But valuations, a recovery in profits, and portfolios that are underweight value stocks could keep the momentum going. However, the type of value stock that does better could shift as the year goes on, from lower-quality to higher-quality stocks that boast stronger returns on assets, equity, and capital, according to a recent client note from Bank of America strategist Savita Subramanian.Investors looking to benefit from a value comeback might want a mix of funds positioned from the different stages of the recovery, in the U.S. and abroad. Here are six funds run by veteran managers with strong track records that have also done well in the past year’s rebound.The $4.3 billionNeuberger Berman Large Cap Valuefund (NPNAX) bet big last year on some of the market’s most unloved sectors and reaped the rewards, returning 84% in the past year and beating 96% of its Morningstar peers.Manager Eli Salzmann focused on sectors like materials, especially copper and gold, that have been starved for capital in recent years as money flocked to technology and consumer-discretionary companies. That “capacity deprivation” sets the stage for sharp margin growth as demand recovers for companies like Freeport-McMoRan (FCX). Not only does the copper miner benefit from a global economic recovery, but it’s also a backdoor into the shift to electric vehicles and clean energy—transitions that will require more copper and could extend the traditional recovery cycle, says Salzmann.A similar trend is at play in energy, a sector that Salzmann says is learning from its mistakes, as companies allocate 60% to 80% of cash flows, rather than all of it, to capital spending.Exxon Mobil(XOM) has been a “dog of the dogs,” pursuing an aggressive growth strategy when investors wanted discipline and a focus on free cash flow, Salzmann says. But now, the company, a top holding, is focusing on its core business and has the right asset mix.When the market fretted over the risks on banks’ loan portfolios last spring, Salzmann went on a shopping spree, adding to financials, including global giants likeBank of America(BAC) andJPMorgan Chase(JPM), as well as regional banks likeTruist Financial(TFC),Comerica(CMA), andRegions Financial(RF) that should get a bigger boost from loan growth and rising interest rates. Salzmann sees a more protracted, broader value recovery as the market enters a higher interest-rate environment amid the unprecedented amounts of fiscal and monetary policy around the world, as well as a period of deglobalization and increased protectionism that will raise prices.Like Salzmann, Herro has been hunting in deeply unloved parts of the market—but abroad. That has taken him to continental Europe and the United Kingdom, which investors have neglected for roughly a decade amid concerns about defaults in countries like Greece, political volatility, and, more recently, Brexit. “It’s almost like the perfect storm after 10 years of a drought. Brexit is behind us, and a lot of what ailed European and international value is now in the rearview,” Herro says.As the U.K. recovers from the pandemic and settles into life outside the European Union, Herro says strong and “severely overcapitalized” banks likeLloyds Banking Group(LYG) andNatWest Group(NWG) will benefit from pent-up demand for investing and borrowing that had been put off amid Brexit uncertainty.Herro has also waded into Chinese internet companies during the sector’s rout in the past year.Alibaba GroupHolding (BABA) andTencent Holdings(700.Hong Kong), which Herro owns through South African internet groupNaspers(NPN.South Africa), have been hit hard in the past year amid regulatory concerns at home and geopolitical tensions with the U.S., creating value in companies with strong business models, he says.Sarah Ketterer, co-manager of the $5.8 billionCauseway International Value(CIVVX), isn’t shopping much in the most battered sectors and isn’t sold on a meaningful rise in interest rates. Ketterer also thinks that the party in cyclicals may be winding down, especially after the 80% gains globally in these economically sensitive stocks since the first Covid-19 vaccine won approval late last year—another reason that traditional value sectors like financials and energy don’t interest her much. These sectors also face constraints to their growth, with energy, for example, facing an expensive long-term transition away from fossil fuels.Instead, Ketterer sees more value these days in European drugmakers likeSanofi(SAN.France),Novartis(NOVN.Switzerland), andRoche Holding(ROG.Switzerland), which have suffered amid postponed elective surgeries and doctors’ visits. The companies are positioned for a recovery but also for a world where vaccines become more important, and ample free cash flow gives these companies the wherewithal to buy machine learning and other tools to speed up drug discovery and cut costs, says Ketterer.Technology companies likeSAP(SAP) are also on her radar. “It’s a legacy software vendor—about as negative as it gets—but 70% of revenues are sticky,” Ketterer says. Plus, Ketterer says the company is led by a young, dynamic CEO, Christian Klein, who is in the early stages of a cloud transition and also taking subsidiaries public, creating what she describes as “one of those rare opportunities.”Unlike Ketterer,Dodge & Cox International Stock(DODFX) co-manager Diana Strandberg still sees upside in some of the cyclical sectors that have led the recovery—like financials, which account for 30% of the fund, including holdings such asBNP Paribas(BNP.France) andUBS Group(UBSG.Switzerland), and emerging market banks like India’sICICI Bank(IBN).Many European and emerging market banks have spent the past decade rebuilding their capital and balance sheets, increasing their returns on assets and earnings power—and doing it in Europe against a negative interest-rate backdrop. Yet Strandberg says investors haven’t noticed that these banks aren’t what they were during the financial crisis. Earnings revisions are rising, yet many still trade at eight to 10 times earnings. Plus, since banks had to hold off on dividends and buybacks during the pandemic, Strandberg sees the possibility of these companies becoming big income stocks as capital distributions are resumed.However, Strandberg cautions against a dogmatic approach and focusing on labels like deep value or relative value—or even classifying certain sectors or companies as value. The $42 billion value fund, which has about a fifth of assets in emerging markets, returned 4.6% on average over the past 15 years, beating 93% of its peers. “Labels are dangerous when you are investing,” Strandberg says. “The starting point matters, and that’s why we are always measuring valuations and fundamentals, but we keep an open mind and not just think we are a value manager so we buy ‘value’ stocks—not only is that changing, but also sometimes stocks are cheap because they should be.”More recently, Strandberg and team have favored pharmaceuticals over consumer staples. While their valuations are similar, Strandberg sees greater upside from drugmakers’ research and development. She has favored companies that are in the midst of a restructuring or ones that are focused on areas like vaccines, immunology, and rare diseases that are more protected from regulatory concerns.Restructuring opportunities are also attractive to T. Rowe Price Value (TRVLX) fund manager Mark Finn. He has been focusing lately on companies in the middle of the value spectrum—those not facing long-term problems—that are misunderstood or addressing self-inflicted problems, likeGeneral Electric(GE), which had made some ill-timed acquisitions and saddled its balance sheet with leverage. Now, though, Finn says that CEO Larry Culp is fixing many of the issues, and the company includes strong businesses like aircraft engines, power, and healthcare.Finn, whose fund returned an average annual 12.1% over the past decade to beat 92% of peers, scooped up banks, discount retailers, and industrials likeDeere(DE) andCaterpillar(CAT) last spring, but is now looking elsewhere. “The cyclicals don’t scream real cheap right now. There’s a lot of optimism built into those.”Instead, Finn sees more value in companies likeProcter & Gamble(PG). The company is cheap, at 20 times cash flow, compared with its historical valuation and is in the midst of a turnaround. It has taken share in its major markets and has an underleveraged balance sheet, Finn says.He also likes utilities such asDominion Energy(D) andXcel Energy(XEL) that have been hit as investors pursue higher-yielding options amid rising interest rates. Also attractive:Sherwin-Williams(SHW), which he says is cheap compared with historical valuations and tethered to the home-building and remodeling boom.While not traditional value fare, technology companies, includingFacebook(FB) andSalesforce.com(CRM), have drawn Finn’s attention. He says Salesforce has a great business model that is well positioned for the recovery, but the stock is in investor no-man’s land, ignored by growth investors and not on value managers’ radar, even though it is in the Russell 1000 Value index.Technology is also a heavy weighting at the $4 billionParnassus Endeavorfund (PARWX), which has beaten 98% of its peers over the past year without owning any energy or materials stocks. Since taking the sole reins after sustainable-investing pioneer Jerome Dodson’s retirement, fund manager Billy Hwan has increased risk management, reducing the heavy concentration in chip companies. Hwan has reallocated some of that money to higher-quality software and service companies likePaychex(PAYX), which he says is well positioned to help companies navigate remote work, flexible hours, and contractor relationships. While chip companies face a risk from continuing U.S.-China tensions, since they get more than half of sales from China, efforts to bolster U.S. chip production could help holdings likeMicron Technology(MU) andIntel(INTC).The fund, which integrates environmental, social, and governance factors into its analysis, steers clear of deep value and areas in secular decline, instead focusing on higher-quality stocks that are misunderstood, likeHanesbrands(HBI). The company had struggled with acquisitions and competition in its underwear business, but new management is reducing the amount of products it sells and focusing on its fast-growing Champion brand, while also trying to cater to a younger demographics, Hwan says.Stimulus has helped cushion household savings and given consumers a bit more to spend as they emerge from the pandemic. Hwan sees 2021 as the year of the consumer, a reason that 10% of the fund is in consumer credit companies likeMastercard(MA),American Express(AXP), andCapital One Financial(COF).For investors looking for comparisons with other value rallies, Hwan sees more similarities between the current comeback and the one in 2000 after the dot-com bubble burst, than the recovery after the global financial crisis that tripped up value managers. “There’s nothing structurally wrong with the economy in terms of credit” as there was after the financial crisis, he says, “so I think the value rotation could last several years.”Only time will tell whether he’s correct in his assessment, but investors may want to take a more holistic view of value as they try to ride the recovery in the near term.Searching for ValueAs the value rally runs on, investors should start gearing up for a shift in the nature of stocks that perform best. Here are six value-focused funds positioned to capitalize on different stages of the recovery.","news_type":1},"isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127480579,"gmtCreate":1624863196092,"gmtModify":1703846475867,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Nio","listText":"Nio","text":"Nio","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127480579","repostId":"1137119316","repostType":4,"repost":{"id":"1137119316","kind":"news","pubTimestamp":1624754401,"share":"https://ttm.financial/m/news/1137119316?lang=&edition=fundamental","pubTime":"2021-06-27 08:40","market":"us","language":"en","title":"Ford Or NIO? The Final Verdict","url":"https://stock-news.laohu8.com/highlight/detail?id=1137119316","media":"seekingalpha","summary":"I am comparing Ford against NIO in different categories.The comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.NIO is growing a lot faster than Ford and the high valuation may be justified.With Ford  launching a major offensive in the market for electric vehicles, Chinese EV maker NIO  will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based ","content":"<p><b>Summary</b></p>\n<ul>\n <li>I am comparing Ford against NIO in different categories.</li>\n <li>The comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.</li>\n <li>NIO is growing a lot faster than Ford and the high valuation may be justified.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5033fa117d7852799244b8275bc1000f\" tg-width=\"1536\" tg-height=\"886\"><span>peterschreiber.media/iStock via Getty Images</span></p>\n<p>With Ford (F) launching a major offensive in the market for electric vehicles, Chinese EV maker NIO (NIO) will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based on market opportunity, scale, revenue model, growth prospects and valuation? I will compare Ford against NIO in each category and issue a final verdict at the end.</p>\n<p><b>Ford vs. NIO: The battle for the global electric vehicle market is heating up</b></p>\n<p>Although there is a world of difference between Ford and NIO, both companies are set to go toe-to-toe in the rapidly growing global electric vehicle market. Ford’s fleet is not yet EV-focused but this is going to change: Feeling that the EV race is heating up, Ford said it is accelerating its electrification plan by investing&nbsp;$30B into its EV manufacturing capabilities until 2025. Ford’s previous capital plan called for a $22B investment in zero-emission vehicles. Ford also set an ambitious sales goal: 40% of its global sales will be electric within the next decade and 33% of pickup truck sales. Electric vehicle sales account for just 1% of Ford's sales today. As Ford is phasing out combustion engines, it is set to evolve into an all-electric vehicle maker by 2040.</p>\n<p><b>Market opportunity</b></p>\n<p>In 2020, 3.2m electric vehicles were sold in the world which represented a small market share of just 4.2%. China, however, was responsible for buying 41% of all electric vehicles in the world in 2020. Chinese buyers purchased 1.3m electric vehicles last year and sales are set to grow fast as Beijing seeks to boost EV adoption. The second largest market for electric vehicles was Europe which accounted for 42% of global EV sales. The US is only the third-largest market for plug-in electric vehicles in the world.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b48c23b32134542f51227d9b1b612887\" tg-width=\"1083\" tg-height=\"863\"><span>(Source: Wikipedia)</span></p>\n<p>China, by far, is the fastest growing EV market in the world, although Europe is catching up fast, in part due to a legislative efforts to increase adoption of zero-emission passenger vehicles and because of massive investments in a Europe-wide charging station network. NIO is&nbsp;on the cusp of entering the European market&nbsp;in a bid to grow market share in the world’s second-largest EV market before the competition is ready.</p>\n<p>Beijing is a driver behind the electrification of the Chinese auto industry: The government wants to see a&nbsp;twenty percent share&nbsp;of electric vehicles for new car sales by 2025 which will drive EV penetration in NIO’s home market.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9871e44eaf69adb27151425887870ace\" tg-width=\"739\" tg-height=\"454\"><span>(Source:Schroders)</span></p>\n<p>Turning to growth projections.</p>\n<p>With more favorable government policies for EV makers in places like China and Europe, these markets are poised to see the fastest sales growth and the highest EV adoption rates in the world. China is not only the largest market due to population size but is also expected to outperform all other markets in the world in EV sales until 2030.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/61d19dff2f34e2d8828aca854e85d84a\" tg-width=\"825\" tg-height=\"565\"><span>(Source:McKinsey)</span></p>\n<p>Since China has a larger total market size, a higher EV adoption rate, stronger expected sales growth and a more favorable regulatory framework, the winner here would be: NIO.</p>\n<p><b>Scale and manufacturing competence</b></p>\n<p>Ford has a century’s worth of manufacturing experience. But Ford, so far, has only one all-electric vehicle in its product line-up that compares to NIO: The Mustang Mach-E SUV. In 2022, Ford will begin to sell the all-electric F-150 Lightening which builds on the success of Ford’s best-selling pick-up truck. NIO already has a stronger product catalog including the 5-seater ES6 SUV, the 5-seater coupe SUV EC6 and the ES8, a 6-seater and 7-seater full-sized SUV.</p>\n<p>Since NIO is solely focused on producing EVs and occupies a very small and defined niche, the Chinese firm has an advantage as far as EV-manufacturing expertise goes. The question is how long this advantage can last. Ford has extensive experience in building cars and can leverage a global manufacturing base to ramp up EV production faster than any niche EV maker could ever hope to achieve. This makes Ford a very serious rival not only to Tesla (TSLA) in the US, but also to NIO abroad. Ford is accelerating its electrification plans and it has the resources and the ambition to become a leader in EVs within the next decade. Ford’s proposed $30B spending on the electrification of its fleet will accelerate its transformation and turn Ford into a long term threat to other EV makers.</p>\n<p>Winner here: Ford.</p>\n<p><b>Differentiation and BaaS revenue model</b></p>\n<p>Both Ford and NIO know about the importance of differentiation in a market that will only get more competitive over time, which is why both companies are investing heavily in a related field that can break or solidify dominance in the EV market: Battery technology.</p>\n<p>Ford is&nbsp;forming a joint venture&nbsp;with South Korean battery technology company SK Innovation to secure supply of traction battery cells and array modules. The joint venture is meant to accelerate battery deliveries and will produce approximately 60 GWh annually, enough to cover 25% of Ford’s estimated annual energy demand by 2030. NIO is also investing in battery technology and has&nbsp;formed its own joint venture&nbsp;to secure battery supply.</p>\n<p>The difference to Ford is that NIO’s battery investment strategy revolves around a battery subscription model, also called “battery-as-a-service”, which creates a strong, long term revenue opportunity for the Chinese vehicle maker. Under this “BaaS” model, users who buy a NIO electric vehicle get a 70,000 RMB initial discount, equivalent to $10,800, and can sign up for a monthly subscription to rent a rechargeable 70 kWh battery. Batteries can then be exchanged at one of NIO’s battery-swapping stations which can be found in most big Chinese cities. A battery subscription costs 980 RMB monthly which is the equivalent of $150.</p>\n<p>The BaaS model has a couple of benefits for both the vehicle maker and the user: Purchasing an electric vehicle from NIO gets a lot more affordable due to the up-front discount and the subscription model ensures that users benefit from advancement in battery technology and better performance over time. Decoupling battery costs from vehicle prices creates an entirely new revenue stream on a subscription basis for NIO. Revenues from “BaaS” subscriptions could be used to increase the density of NIO’s network of charging/replacement stations. The battery subscription model also binds customers to NIO, potentially increasing customer lifetime value.</p>\n<p>Ford and NIO are primed to benefit from falling battery costs for electric vehicles as they ramp up capital allocations. As more investments flow into developing more efficient batteries, performance will go up and costs will go down which should drive EV adoption and benefit all EV makers. This is because lower battery prices make EVs more competitive to passenger vehicles with combustion engines. But since NIO is structuring a part of its business model explicitly around battery subscriptions, NIO could benefit more than Ford.</p>\n<p>Battery costs for EVs have decreased 70% since 2014, based on information provided by investment firm Schroders, and are set to decrease more this decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c42acb75905affe7570a2f399ea3192f\" tg-width=\"758\" tg-height=\"449\"><span>(Source: Schroders)</span></p>\n<p>The “BaaS” model is genius and could develop into a $500M a year revenue opportunity for NIO long term. Although Ford is ramping up its investments in battery technology, the winner in this category is: NIO.</p>\n<p><b>Sales growth and valuation</b></p>\n<p>Ford’s sales in May grew 4.1% Y/Y but electrified vehicle sales (including hybrids) surged 184% Y/Y as Ford sold a record 10,364 EVs/hybrids in May. Escape electrified sales and Explorer Hybrid grew sales at 125% and 132% Y/Y showing strong customer uptake. NIO delivered 6,711 vehicles last month including 3,017 ES6s, 1,412 ES8s and 2,282 EC6s. Total Y/Y delivery growth for May was 95.3%.</p>\n<p>Ford's sales are fifty-four times larger than NIO's which creates more sales growth and revaluation potential for NIO.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df5a0a393e44ed74241c5effcdd92350\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p>\n<p>The difference in valuation between Ford and NIO is like the difference between night and day. This is because Ford is still seen as a mature vehicle maker with expected enterprise sales growth in the low-to-mid digits, despite explosive growth in the EV category. Ford is expected to grow revenues by 33% until FY 2025 (base year: FY 2020) and NIO by 808%!</p>\n<p>Due to these differences in sales growth, NIO is the complete opposite of Ford, at least as far as valuation goes. The Chinese EV-maker is expected to see sales and delivery growth close to 100% this year and since NIO is only dealing in EVs, NIO gets a much higher market-cap-to-sales ratio than Ford.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/817605c6b1e82c03d0473ea570d32b8f\" tg-width=\"506\" tg-height=\"406\"><span>(Source: Author)</span></p>\n<p><b>NIO has larger risks...</b></p>\n<p>NIO is the more risky venture, but also the one that offers the most promise. Government policy favors EV-makers like NIO. The potential for total global sales growth is larger for NIO as it operates from a smaller revenue base compared to Ford. But there are also a few things that work against NIO. For example, recalls due to production defects would be a much bigger challenge for NIO to overcome than for Ford which can rely on a global service and distribution network. NIO’s valuation is also not without risk as an unexpected slowing of sales growth due to production setbacks would leave a much larger dent in the financials.</p>\n<p><b>Final verdict</b></p>\n<p>NIO is definitely the more “sexy” vehicle maker. Strong adoption and sales growth in China and Europe support NIO. Its super smart BaaS model which decouples vehicle purchase prices from battery costs is genius. You pay a high price for this growth but the market opportunity for NIO is immense.</p>\n<p>Ford’s EV sales are booming and the percentage of EV sales will increase as the vehicle maker electrifies its fleet. Ford has a lot of potential in the EV market but since EV sales are still a relatively low percentage of total sales, it will take a long time for Ford to complete its transformation.</p>\n<p>If you believe in the potential of the global EV market, buy NIO. If you believe in the potential of the global EV market and don’t like much risk, buy Ford.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford Or NIO? The Final Verdict</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord Or NIO? The Final Verdict\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nI am comparing Ford against NIO in different categories.\nThe comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车","NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4436600-ford-or-nio-the-final-verdict","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137119316","content_text":"Summary\n\nI am comparing Ford against NIO in different categories.\nThe comparison is intended to improve the understanding of Ford's and NIO's growth potential while highlighting differences in market position and opportunities.\nNIO is growing a lot faster than Ford and the high valuation may be justified.\n\npeterschreiber.media/iStock via Getty Images\nWith Ford (F) launching a major offensive in the market for electric vehicles, Chinese EV maker NIO (NIO) will face one more rival competing for sales in the future. Which vehicle maker offers the best deal based on market opportunity, scale, revenue model, growth prospects and valuation? I will compare Ford against NIO in each category and issue a final verdict at the end.\nFord vs. NIO: The battle for the global electric vehicle market is heating up\nAlthough there is a world of difference between Ford and NIO, both companies are set to go toe-to-toe in the rapidly growing global electric vehicle market. Ford’s fleet is not yet EV-focused but this is going to change: Feeling that the EV race is heating up, Ford said it is accelerating its electrification plan by investing $30B into its EV manufacturing capabilities until 2025. Ford’s previous capital plan called for a $22B investment in zero-emission vehicles. Ford also set an ambitious sales goal: 40% of its global sales will be electric within the next decade and 33% of pickup truck sales. Electric vehicle sales account for just 1% of Ford's sales today. As Ford is phasing out combustion engines, it is set to evolve into an all-electric vehicle maker by 2040.\nMarket opportunity\nIn 2020, 3.2m electric vehicles were sold in the world which represented a small market share of just 4.2%. China, however, was responsible for buying 41% of all electric vehicles in the world in 2020. Chinese buyers purchased 1.3m electric vehicles last year and sales are set to grow fast as Beijing seeks to boost EV adoption. The second largest market for electric vehicles was Europe which accounted for 42% of global EV sales. The US is only the third-largest market for plug-in electric vehicles in the world.\n(Source: Wikipedia)\nChina, by far, is the fastest growing EV market in the world, although Europe is catching up fast, in part due to a legislative efforts to increase adoption of zero-emission passenger vehicles and because of massive investments in a Europe-wide charging station network. NIO is on the cusp of entering the European market in a bid to grow market share in the world’s second-largest EV market before the competition is ready.\nBeijing is a driver behind the electrification of the Chinese auto industry: The government wants to see a twenty percent share of electric vehicles for new car sales by 2025 which will drive EV penetration in NIO’s home market.\n(Source:Schroders)\nTurning to growth projections.\nWith more favorable government policies for EV makers in places like China and Europe, these markets are poised to see the fastest sales growth and the highest EV adoption rates in the world. China is not only the largest market due to population size but is also expected to outperform all other markets in the world in EV sales until 2030.\n(Source:McKinsey)\nSince China has a larger total market size, a higher EV adoption rate, stronger expected sales growth and a more favorable regulatory framework, the winner here would be: NIO.\nScale and manufacturing competence\nFord has a century’s worth of manufacturing experience. But Ford, so far, has only one all-electric vehicle in its product line-up that compares to NIO: The Mustang Mach-E SUV. In 2022, Ford will begin to sell the all-electric F-150 Lightening which builds on the success of Ford’s best-selling pick-up truck. NIO already has a stronger product catalog including the 5-seater ES6 SUV, the 5-seater coupe SUV EC6 and the ES8, a 6-seater and 7-seater full-sized SUV.\nSince NIO is solely focused on producing EVs and occupies a very small and defined niche, the Chinese firm has an advantage as far as EV-manufacturing expertise goes. The question is how long this advantage can last. Ford has extensive experience in building cars and can leverage a global manufacturing base to ramp up EV production faster than any niche EV maker could ever hope to achieve. This makes Ford a very serious rival not only to Tesla (TSLA) in the US, but also to NIO abroad. Ford is accelerating its electrification plans and it has the resources and the ambition to become a leader in EVs within the next decade. Ford’s proposed $30B spending on the electrification of its fleet will accelerate its transformation and turn Ford into a long term threat to other EV makers.\nWinner here: Ford.\nDifferentiation and BaaS revenue model\nBoth Ford and NIO know about the importance of differentiation in a market that will only get more competitive over time, which is why both companies are investing heavily in a related field that can break or solidify dominance in the EV market: Battery technology.\nFord is forming a joint venture with South Korean battery technology company SK Innovation to secure supply of traction battery cells and array modules. The joint venture is meant to accelerate battery deliveries and will produce approximately 60 GWh annually, enough to cover 25% of Ford’s estimated annual energy demand by 2030. NIO is also investing in battery technology and has formed its own joint venture to secure battery supply.\nThe difference to Ford is that NIO’s battery investment strategy revolves around a battery subscription model, also called “battery-as-a-service”, which creates a strong, long term revenue opportunity for the Chinese vehicle maker. Under this “BaaS” model, users who buy a NIO electric vehicle get a 70,000 RMB initial discount, equivalent to $10,800, and can sign up for a monthly subscription to rent a rechargeable 70 kWh battery. Batteries can then be exchanged at one of NIO’s battery-swapping stations which can be found in most big Chinese cities. A battery subscription costs 980 RMB monthly which is the equivalent of $150.\nThe BaaS model has a couple of benefits for both the vehicle maker and the user: Purchasing an electric vehicle from NIO gets a lot more affordable due to the up-front discount and the subscription model ensures that users benefit from advancement in battery technology and better performance over time. Decoupling battery costs from vehicle prices creates an entirely new revenue stream on a subscription basis for NIO. Revenues from “BaaS” subscriptions could be used to increase the density of NIO’s network of charging/replacement stations. The battery subscription model also binds customers to NIO, potentially increasing customer lifetime value.\nFord and NIO are primed to benefit from falling battery costs for electric vehicles as they ramp up capital allocations. As more investments flow into developing more efficient batteries, performance will go up and costs will go down which should drive EV adoption and benefit all EV makers. This is because lower battery prices make EVs more competitive to passenger vehicles with combustion engines. But since NIO is structuring a part of its business model explicitly around battery subscriptions, NIO could benefit more than Ford.\nBattery costs for EVs have decreased 70% since 2014, based on information provided by investment firm Schroders, and are set to decrease more this decade.\n(Source: Schroders)\nThe “BaaS” model is genius and could develop into a $500M a year revenue opportunity for NIO long term. Although Ford is ramping up its investments in battery technology, the winner in this category is: NIO.\nSales growth and valuation\nFord’s sales in May grew 4.1% Y/Y but electrified vehicle sales (including hybrids) surged 184% Y/Y as Ford sold a record 10,364 EVs/hybrids in May. Escape electrified sales and Explorer Hybrid grew sales at 125% and 132% Y/Y showing strong customer uptake. NIO delivered 6,711 vehicles last month including 3,017 ES6s, 1,412 ES8s and 2,282 EC6s. Total Y/Y delivery growth for May was 95.3%.\nFord's sales are fifty-four times larger than NIO's which creates more sales growth and revaluation potential for NIO.\nData by YCharts\nThe difference in valuation between Ford and NIO is like the difference between night and day. This is because Ford is still seen as a mature vehicle maker with expected enterprise sales growth in the low-to-mid digits, despite explosive growth in the EV category. Ford is expected to grow revenues by 33% until FY 2025 (base year: FY 2020) and NIO by 808%!\nDue to these differences in sales growth, NIO is the complete opposite of Ford, at least as far as valuation goes. The Chinese EV-maker is expected to see sales and delivery growth close to 100% this year and since NIO is only dealing in EVs, NIO gets a much higher market-cap-to-sales ratio than Ford.\n(Source: Author)\nNIO has larger risks...\nNIO is the more risky venture, but also the one that offers the most promise. Government policy favors EV-makers like NIO. The potential for total global sales growth is larger for NIO as it operates from a smaller revenue base compared to Ford. But there are also a few things that work against NIO. For example, recalls due to production defects would be a much bigger challenge for NIO to overcome than for Ford which can rely on a global service and distribution network. NIO’s valuation is also not without risk as an unexpected slowing of sales growth due to production setbacks would leave a much larger dent in the financials.\nFinal verdict\nNIO is definitely the more “sexy” vehicle maker. Strong adoption and sales growth in China and Europe support NIO. Its super smart BaaS model which decouples vehicle purchase prices from battery costs is genius. You pay a high price for this growth but the market opportunity for NIO is immense.\nFord’s EV sales are booming and the percentage of EV sales will increase as the vehicle maker electrifies its fleet. Ford has a lot of potential in the EV market but since EV sales are still a relatively low percentage of total sales, it will take a long time for Ford to complete its transformation.\nIf you believe in the potential of the global EV market, buy NIO. If you believe in the potential of the global EV market and don’t like much risk, buy Ford.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124347280,"gmtCreate":1624749864240,"gmtModify":1703844287882,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Too the moon","listText":"Too the moon","text":"Too the moon","images":[{"img":"https://static.tigerbbs.com/ad88954b860291e3c4cbf03d2de7d640","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124347280","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167557395,"gmtCreate":1624279256617,"gmtModify":1703832246818,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Bullish","listText":"Bullish","text":"Bullish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167557395","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168843439,"gmtCreate":1623972504221,"gmtModify":1703824889566,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Bear or bull now&nbsp;","listText":"Bear or bull now&nbsp;","text":"Bear or bull now","images":[{"img":"https://static.tigerbbs.com/7105443940aa52cf5330961d9f3fa436","width":"1125","height":"2785"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168843439","isVote":1,"tweetType":1,"viewCount":495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":168840066,"gmtCreate":1623972418355,"gmtModify":1703824884602,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ARKK\">$ARK Innovation ETF(ARKK)$</a>Pls soar","listText":"<a href=\"https://laohu8.com/S/ARKK\">$ARK Innovation ETF(ARKK)$</a>Pls soar","text":"$ARK Innovation ETF(ARKK)$Pls soar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168840066","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":133114590,"gmtCreate":1621727317410,"gmtModify":1704361704816,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Lookin good","listText":"Lookin good","text":"Lookin good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/133114590","isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192159557,"gmtCreate":1621166750779,"gmtModify":1704353546540,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Now ? Or never&nbsp;","listText":"Now ? Or never&nbsp;","text":"Now ? Or never","images":[{"img":"https://static.tigerbbs.com/9941b78171b3d7d24573e71d6ad68ff3","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192159557","isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190447923,"gmtCreate":1620648534462,"gmtModify":1704346068438,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"It was good now trash?","listText":"It was good now trash?","text":"It was good now trash?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190447923","repostId":"1106333988","repostType":2,"repost":{"id":"1106333988","kind":"news","pubTimestamp":1620617869,"share":"https://ttm.financial/m/news/1106333988?lang=&edition=fundamental","pubTime":"2021-05-10 11:37","market":"us","language":"en","title":"Bearish Bets: 2 Tech Stocks You Should Consider Shorting This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1106333988","media":"realmoney","summary":"Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opp","content":"<p>Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.</p>\n<p>Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet'sQuant Ratings, we zero in on five names.</p>\n<p>While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.</p>\n<p><b>Alteryx</b></p>\n<p>Alteryx Inc. (AYX) &nbsp;recently was downgraded to<b>Sell</b>with a D+ rating by TheStreet's<b>Quant Ratings.</b></p>\n<p><img src=\"https://static.tigerbbs.com/7afc1fc2f19b5149d4cb10eea02cc5d7\" tg-width=\"986\" tg-height=\"889\" referrerpolicy=\"no-referrer\"></p>\n<p>This provider of analytics platforms has fallen hard since peaking in early February. Rough earnings stoked the selling and it has been straight down ever since. The channel is not symmetrical, but we can see a series of lower highs and lower lows.</p>\n<p>Money flow is poor and the Relative Strength Index (RSI) cannot seem to get going. This tells us Alteryx is relatively poor versus the rest of the market. Moving average convergence divergence (MACD) is on a sell signal and the cloud is deep red.</p>\n<p>If short, target a move to $65 or so but put in a stop at $83.</p>\n<p><b>Pinterest</b></p>\n<p>Pinterest Inc.&nbsp; (PINS) &nbsp;recently was downgraded to<b>Sell</b>with a D+ rating by TheStreet's<b>Quant Ratings.</b></p>\n<p><img src=\"https://static.tigerbbs.com/6b1e181ed1151d1395ae59a7035382df\" tg-width=\"999\" tg-height=\"891\" referrerpolicy=\"no-referrer\"></p>\n<p>The company behind the popular app of the same name has been beaten like a piñata lately, with a gap lower on earnings and not much energy from the dip buyers. The stock continues to be distributed with high volume and a MACD sell signal.</p>\n<p>The cloud just turned red and the 200-day moving average is not far below here. A gap is still open in the $40s and that could be the place to target if short.</p>\n<p>Put in a stop at $75 just in case.</p>","source":"lsy1619508253632","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bearish Bets: 2 Tech Stocks You Should Consider Shorting This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBearish Bets: 2 Tech Stocks You Should Consider Shorting This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 11:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580><strong>realmoney</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.\nUsing technical analysis of the charts of those stocks, and, when ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AYX":"Alteryx Inc.","PINS":"Pinterest, Inc."},"source_url":"https://realmoney.thestreet.com/investing/stocks/bearish-bets-2-tech-stocks-you-should-consider-shorting-this-week-15648580","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106333988","content_text":"Each weekTrifecta Stocksidentifies names that look bearish and may present interesting investing opportunities on the short side.\nUsing technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet'sQuant Ratings, we zero in on five names.\nWhile we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.\nAlteryx\nAlteryx Inc. (AYX)  recently was downgraded toSellwith a D+ rating by TheStreet'sQuant Ratings.\n\nThis provider of analytics platforms has fallen hard since peaking in early February. Rough earnings stoked the selling and it has been straight down ever since. The channel is not symmetrical, but we can see a series of lower highs and lower lows.\nMoney flow is poor and the Relative Strength Index (RSI) cannot seem to get going. This tells us Alteryx is relatively poor versus the rest of the market. Moving average convergence divergence (MACD) is on a sell signal and the cloud is deep red.\nIf short, target a move to $65 or so but put in a stop at $83.\nPinterest\nPinterest Inc.  (PINS)  recently was downgraded toSellwith a D+ rating by TheStreet'sQuant Ratings.\n\nThe company behind the popular app of the same name has been beaten like a piñata lately, with a gap lower on earnings and not much energy from the dip buyers. The stock continues to be distributed with high volume and a MACD sell signal.\nThe cloud just turned red and the 200-day moving average is not far below here. A gap is still open in the $40s and that could be the place to target if short.\nPut in a stop at $75 just in case.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190088806,"gmtCreate":1620553191105,"gmtModify":1704344920087,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Software is the best&nbsp;","listText":"Software is the best&nbsp;","text":"Software is the best","images":[{"img":"https://static.tigerbbs.com/46b8fd859467b6a79bbce92a9ddd3531","width":"1125","height":"2605"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190088806","isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190088921,"gmtCreate":1620553139063,"gmtModify":1704344919764,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Coins","listText":"Coins","text":"Coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/190088921","isVote":1,"tweetType":1,"viewCount":470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":104536972,"gmtCreate":1620397157696,"gmtModify":1704343137097,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Red is my new colour","listText":"Red is my new colour","text":"Red is my new colour","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/104536972","isVote":1,"tweetType":1,"viewCount":478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108246630,"gmtCreate":1620034507220,"gmtModify":1704337654971,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Buy the dips on blockvhain stocks","listText":"Buy the dips on blockvhain stocks","text":"Buy the dips on blockvhain stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108246630","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370555499,"gmtCreate":1618614990811,"gmtModify":1704713354391,"author":{"id":"3566354699453607","authorId":"3566354699453607","name":"Llwwhh","avatar":"https://static.tigerbbs.com/1d3d8d4d183bc10e20b0e10d8861ab03","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566354699453607","authorIdStr":"3566354699453607"},"themes":[],"htmlText":"Solid&nbsp;","listText":"Solid&nbsp;","text":"Solid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/370555499","repostId":"1151923129","repostType":4,"repost":{"id":"1151923129","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618581789,"share":"https://ttm.financial/m/news/1151923129?lang=&edition=fundamental","pubTime":"2021-04-16 22:03","market":"us","language":"en","title":"Bionano Genomics fell about 10% in Friday morning  trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151923129","media":"Tiger Newspress","summary":"(April 16) Bionano Genomics fell about 10% in Friday morning trading.\nThere's a genomics revolution ","content":"<p>(April 16)&nbsp;Bionano Genomics&nbsp;fell&nbsp;about&nbsp;10%&nbsp;in Friday morning trading.</p>\n<p>There's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b>(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p>\n<p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p>\n<p>Many investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p>\n<p><img src=\"https://static.tigerbbs.com/4d6d3a8298b2b720b7b4ddcf26507750\" tg-width=\"708\" tg-height=\"500\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics fell about 10% in Friday morning  trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics fell about 10% in Friday morning  trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-16 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(April 16)&nbsp;Bionano Genomics&nbsp;fell&nbsp;about&nbsp;10%&nbsp;in Friday morning trading.</p>\n<p>There's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b>(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p>\n<p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p>\n<p>Many investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p>\n<p><img src=\"https://static.tigerbbs.com/4d6d3a8298b2b720b7b4ddcf26507750\" tg-width=\"708\" tg-height=\"500\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151923129","content_text":"(April 16) Bionano Genomics fell about 10% in Friday morning trading.\nThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics(NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.\nBionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.\nMany investors remain enthusiastic about the company's prospects. Bionanobeat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}